Yale University

Daniel Rowe Duncan

Tarek M Fahmy

Christopher K Breuer

Michael Simons

Pei-Yu Chen

Joseph Patterson

Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF&#x3b2; inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

Growing community of inventors

Boston, MA, United States of America

Daniel Rowe Duncan